Image 7_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…"

Image 6_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…"

Image 3_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…"

Image 1_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…"

Image 2_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…"

Image 4_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…"

Image 5_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…"

Image 8_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif حسب Ying Ye (72583)

"…</p>Methods<p>In this study, we applied the HuProt array and the bioinformatics analysis to assess the diagnostic values of the decreased autoantibodies in lung cancers.…"

Source data for Fig 4C. حسب Isabel Raposo (21615517)

Source data for Fig 1C. حسب Isabel Raposo (21615517)

Growth kinetics of YFV-17D/Asibi chimeras in C6/36 cells. حسب Anja vom Hemdt (19787189)

الموضوعات:

Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage. حسب Verónica M. Negrón-Pérez (20691412)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)

"…However, there is concern that by neutralizing the SARS-CoV-2 virus, nMAbs may decrease the availability of antigens to the immune system, potentially impairing the endogenous polyclonal immune response and decreasing long-term immune protection.…"

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)